Innovate UK Biomedical Catalyst Future Medicines Accelerator
Applications open 1st September.
Deadline for submission: 12pm 26th September 2025
Overview
LYVA Labs, in partnership with Innovate UK and a consortium of internationally recognised scientific, technical, and commercial experts, is proud to launch the Innovate UK Biomedical Catalyst Future Medicines Accelerator.
The Biomedical Catalyst is Innovate UK’s flagship grant funding mechanism, designed to accelerate innovation and help UK companies bring products to market more efficiently.
Part of the Innovate UK Biomedical Catalyst, Accelerators help SMEs, spinouts, and academic innovators develop and test innovative health and care solutions across therapeutics, medical devices, diagnostics, and digital health. Through thematic Accelerators, participants gain tailored support to refine their ideas, explore market viability, and prepare for clinical or commercial validation.
Who is this for?
UK-based SMEs (as defined by Innovate UK).
Academics in the early stages of forming an SME.
Start-ups developing innovations within the scope of Future Medicines addressing clear and evidenced healthcare challenges.
At early-stage Technology Readiness Levels typically TRL2-4
Companies with technologies, products, processes, or services that have a commercial route to market.
Organisations working in radiopharmaceuticals innovation particularly encouraged.
Sectors in-scope
The development, discovery or manufacturing of a broad range of next-generation medical treatments, technologies, products, processes, or services to address increasingly complex diseases, usually leveraging advanced scientific approaches for more targeted, effective therapies tailored to individual patient needs.
Examples include (but are not restricted to) the fields below. We are particularly interested in applicants working in Radiopharmaceuticals.
.png?width=200&height=200&name=Launch%20post%20(4).png)
Radiopharmaceuticals
.png?width=200&height=200&name=Launch%20post%20(5).png)
Microbiome and Phage-based therapies
Biopharmaceuticals
Regenerative and Personalised Medicines
Gene therapies and CAR-T cell therapies
Antimicrobial resistance
Programme Structure
Pre-Accelerator (Nov 2025 – Dec 2025):
Companies will build a strong foundation in drug discovery, development, regulation, market strategy, and exploitation planning, with guidance on grants, early-stage financing, and investment readiness - while establishing a peer network.
Accelerator (Jan 2026 –Mar 2026):
A select group from the Pre-Accelerator will receive tailored technical, scientific, and commercial support, a detailed R&D and exploitation plan, support to draft grant applications, investor pitch training, sector-specific introductions, and a personalised pack to support future funding.
What you receive on the Accelerator
-
World-leading expertise in drug discovery, development, and regulation
-
Market research, competitive analysis, and commercial strategy support
-
Investment readiness training, pitch preparation, and funding guidance
- Support to draft a grant application
-
Access to cutting-edge research facilities and networking with sector experts
-
The opportunity to work with partners to develop technical roadmaps
-
Face-to-face peer and investor events
About Innovate UK
Innovate UK, part of UK Research and Innovation (UKRI), is the UK’s innovation agency. It works to create a better future by inspiring, involving and investing in businesses developing life-changing innovations. Its mission is to help companies to grow through their development and commercialisation of new products, processes and services, supported by an outstanding innovation ecosystem that is agile, inclusive and easy to navigate.
Innovate UK: inspiring business innovation.
Applications will open on 1st September 2025.
Please return to this page from 1st September when we will share a link to the application form.
Any queries should be sent to futuremedicines.accelerator@lyvalabs.com